Sugi Predict

Sugi Predict / Compounds / SCHEMBL7318932

SCHEMBL7318932

SCHEMBL7318932

CCc1nn(C)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 3/20 0.44
▸ GABRD O14764 3/20 0.44
▸ GABRA1 P14867 3/20 0.44
▸ GABRB1 P18505 3/20 0.44
▸ GABRG2 P18507 3/20 0.44
▸ GABRB3 P28472 3/20 0.44
▸ GABRA5 P31644 3/20 0.44
▸ GABRA3 P34903 3/20 0.44
▸ GABRA2 P47869 3/20 0.44
▸ GABRB2 P47870 3/20 0.44
▸ GABRA4 P48169 3/20 0.44
▸ GABRE P78334 3/20 0.44
▸ GABRA6 Q16445 3/20 0.44
▸ GABRG1 Q8N1C3 3/20 0.44
▸ GABRG3 Q99928 3/20 0.44
▸ GABRQ Q9UN88 3/20 0.44
▸ GAA P10253 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ NR4A3 Q92570 1/20 0.37
▸ RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15884366 0.85 L3MBTL1 (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL21190115 0.84 GAA (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26404842 0.82 ADORA2A (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4655564 0.82 GAA (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15884353 0.82 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL27788040 0.81 L3MBTL1 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL28363146 0.81 GAA (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17786799 0.81 GAA (0.40) GAAL3MBTL1RAB9ACYP1A2CYP2C9
SCHEMBL5906656 0.79 GABRP (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15884425 0.79 GAA (0.36) GAARAB9ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 — — EP disclosed
EP-4007758-B1 BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER MERSANA THERAPEUTICS INC (US) 2026-05-13 — — EP disclosed
US-20250011339-A1 STING AGONIST COMPOUNDS AND METHODS OF USE MERSANA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
US-11939343-B2 Sting agonist compounds and methods of use MERSANA THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 — — CN disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
CN-112118845-B MCL-1 inhibitors 吉利德科学公司 2023-06-13 — — CN disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-20220340535-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2022-10-27 — — US disclosed
EP-4029868-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-07-20 — — EP disclosed
US-20150322063-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF FUJIFILM CORPORATION (JP) 2015-11-12 — — US disclosed
US-20150322063-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF FUJIFILM CORPORATION (JP) 2015-11-12 — — US disclosed
WO-2014109414-A1 NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF 富士フイルム株式会社 (JP) 2014-07-17 — — WO disclosed
WO-2012143395-A1 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2012-10-26 — — WO disclosed
US-8269013-B2 Substituted pyrazole inhibitors of c-Met protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 — — US disclosed
US-8269013-B2 Substituted pyrazole inhibitors of c-Met protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 — — US disclosed
WO-2010138663-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 — — WO disclosed
US-20100305155-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 — — US disclosed
US-20100305155-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 — — US disclosed
US-20010044445-A1 AZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES 2001-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 GABRP 3749/4885GABRD 4190/4885GABRA1 4235/4885
US-20100305155-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE MET, BRAF, DMPK GABRP 2093/4885GABRD 3321/4885GABRA1 3239/4885
US-11939343-B2 Sting agonist compounds and methods of use STING1, IRF3, MAVS GABRP 808/4885GABRD 867/4885GABRA1 956/4885
US-11643400-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 GABRP 3749/4885GABRD 4190/4885GABRA1 4235/4885
US-20150322063-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF NPM1, NAP1L1, REN GABRP 3417/4885GABRD 4375/4885GABRA1 2363/4885
US-20250011339-A1 STING AGONIST COMPOUNDS AND METHODS OF USE STING1, IRF3, MAVS GABRP 808/4885GABRD 867/4885GABRA1 956/4885
US-20010044445-A1 AZOLE INHIBITORS OF CYTOKINE PRODUCTION IL5, IL2, IL4 GABRP 3082/4885GABRD 3262/4885GABRA1 1962/4885
US-20220340535-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 GABRP 3749/4885GABRD 4190/4885GABRA1 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.